医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

InnoCare to Present at the Morgan Stanley 2020 Virtual Asia Pacific Conference & ZGC Forum

2020年09月17日 PM05:51
このエントリーをはてなブックマークに追加


 

BEIJING

InnoCare Pharmaceuticals (HKEX: 09969), a clinical stage biopharmaceutical company committed to discovering, developing, and commercializing innovative medicines for the treatment of cancer and autoimmune diseases, announced today that the company will present at the upcoming Morgan Stanley 2020 Virtual Asia Pacific Conference and ZGC Forum.

InnoCare CFO, Mr. Shaojing Tong, will join the China Biotech Panel of the Morgan Stanley conference to discuss and share the insights of China’s booming biotech industry on Thursday, September 24, 2020 China time.

Meanwhile, InnoCare will exhibit innovative medicine at the ZGC forum from September 17-20 in Beijing. Dr. Renbin Zhao, Executive Director of Biology and Clinical Development Strategy of InnoCare will present on the latest development of BTK inhibitor Orelabrutinib on the afternoon of Thursday, September 17, 2020, China time.

Founded in 2007, the ZGC forum has been held for years with the mission to promote communication, exchange, and cooperation in the field of science and technology worldwide.

About InnoCare Pharma

InnoCare Pharmaceuticals is a clinical stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune disease with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200917005364/en/

CONTACT

Media

Chunhua Lu

86-10-66609879

chunhua.lu@innocarepharma.com

Investor Relations

86-10-66609999

ir@innocarepharma.com

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024